Animal diseases

Zero-Contact Medical Station for a Safe and Rapid PCR Covid-19 Testing

Retrieved on: 
Thursday, May 6, 2021
Bat virome, Sarbecovirus, Severe acute respiratory syndrome, Infectious diseases, Medical specialties, Animal diseases

He adds that "Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff.

Key Points: 
  • He adds that "Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff.
  • This allows the medical staff to achieve nasal swabbing without patient contact and eliminates the need to wear a PPE.
  • Nasal Swab Robot just obtained the CE mark with Class I.\nThe Zero-Contact Medical Station achieves zero-contact swabbing and pipettingtasks for lab technicians.
  • To find out more about the Zero-Contact Medical Station, please visit our website https://brainnavi.com/zerocontactstation/ .\n'

Zero-Contact Medical Station for a Safe and Rapid PCR Covid-19 Testing

Retrieved on: 
Thursday, May 6, 2021
Bat virome, Sarbecovirus, Severe acute respiratory syndrome, COVID-19, Health, Animal diseases, Medical specialties

He adds that "Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff.

Key Points: 
  • He adds that "Since the SARS crisis in Asia 17 years ago, there was no advancement in the protection technology for medical staff.
  • This allows the medical staff to achieve nasal swabbing without patient contact and eliminates the need to wear a PPE.
  • Nasal Swab Robot just obtained the CE mark with Class I.\nThe Zero-Contact Medical Station achieves zero-contact swabbing and pipettingtasks for lab technicians.
  • To find out more about the Zero-Contact Medical Station, please visit our website https://brainnavi.com/zerocontactstation/ .\nView original content to download multimedia: http://www.prnewswire.com/news-releases/zero-contact-medical-station-for...\nSOURCE Brain Navi Biotechnology Co., Ltd.\n'

NEC Contributes to Development of Artificial DNA Aptamer that Binds to the Novel Coronavirus (SARS-CoV-2)

Retrieved on: 
Thursday, May 6, 2021
Sarbecovirus, Zoonoses, Animal diseases, Bat virome, Veterinary medicine, Biotechnology, Nucleic acids, Aptamer, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome–related coronavirus, Coronavirus, Middle East respiratory syndrome–related coronavirus

b'TOKYO, May 6, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) and NEC Solution Innovators today announced the successful development of artificial DNA aptamers (1) that bind to the novel coronavirus (SARS-CoV-2).

Key Points: 
  • b'TOKYO, May 6, 2021 - (JCN Newswire) - NEC Corporation (TSE: 6701) and NEC Solution Innovators today announced the successful development of artificial DNA aptamers (1) that bind to the novel coronavirus (SARS-CoV-2).
  • This aptamer uses a new modified base called Base appended Base ((5), Patent No.
  • In fiscal 2021, NEC expects to provide a prototype of a fixed-type spatial monitoring measuring device for companies, universities and other research institutions that perform virus measurement and other measures.
  • For more information, visit NEC at https://www.nec.com.\n'

Dell Technologies and i2b2 tranSMART Foundation Create "Digital Twins" to Treat Long-Haul COVID-19

Retrieved on: 
Wednesday, May 5, 2021
Sarbecovirus, Respiratory diseases, COVID-19, Zoonoses, Long Covid, Animal diseases, PASC, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Simulation

"Working together with the i2b2tranSMART Foundation,we will apply ourexpertiseand technologyto build digital twins, share data, conduct simulations and analyses using these insights to helpunderstand and better treat patients with long-haul COVID.

Key Points: 
  • "Working together with the i2b2tranSMART Foundation,we will apply ourexpertiseand technologyto build digital twins, share data, conduct simulations and analyses using these insights to helpunderstand and better treat patients with long-haul COVID.
  • So-called long haulers suffer from what is known formally as Post-Acute Sequelae of SARS-CoV-2 (PASC).
  • "This new AI-driven platform will help them use the explosion of research findings to deliver better care and precision treatments for their patients.
  • By creating these digital twins, we are taking clinical research to a whole new level.

Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID-19 therapy via donations and licensing agreements

Retrieved on: 
Tuesday, May 4, 2021
Animal diseases, Medical specialties, Clinical medicine, HIV/AIDS, Zoonoses, Immune system disorders, Immunology, Opportunistic infection, Histoplasmosis, Candidiasis, Esophageal candidiasis, Cryptococcosis

"We hope that our donations as well as collaborations with other organizations speed access to baricitinib and provide treatment options for these patients.

Key Points: 
  • "We hope that our donations as well as collaborations with other organizations speed access to baricitinib and provide treatment options for these patients.
  • Follow dose adjustments as recommended in the Fact Sheet for Healthcare Providers for patients with abnormal renal, hematological and hepatic laboratory values.
  • Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus and BK virus were reported with Olumiant.
  • However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of research, development and commercialization.

Oragenics Announce Changes in Management and Board of Directors

Retrieved on: 
Monday, May 3, 2021
Health, Pharmaceutical, Zoonoses, Veterinary medicine, Animal diseases, Health sciences, Animal virology, Coronavirus, Middle East respiratory syndrome–related coronavirus, COVID-19

Mr. Sullivan, the Company\xe2\x80\x99s current Chief Financial Officer, will serve as the Company\xe2\x80\x99s interim principal executive officer to address the vacancy created by Dr. Joslyn\xe2\x80\x99s resignation.\nSpeaking for the Board of Directors, Dr.

Key Points: 
  • Mr. Sullivan, the Company\xe2\x80\x99s current Chief Financial Officer, will serve as the Company\xe2\x80\x99s interim principal executive officer to address the vacancy created by Dr. Joslyn\xe2\x80\x99s resignation.\nSpeaking for the Board of Directors, Dr.
  • The Company is dedicated to the development and commercialization of a vaccine candidate providing specific immunity from novel coronavirus.
  • The Terra CoV-2 immunization leverages coronavirus spike protein research conducted by the National Institutes of Health.
  • In addition, Oragenics has an exclusive worldwide channel collaboration with Eleszto Genetika, Inc. relating to the development of novel lantibiotics.\nFor more information about Oragenics, please visit www.oragenics.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210503005308/en/\n'

Taconic Biosciences Launches New COVID-19 Mouse Model

Retrieved on: 
Thursday, April 29, 2021
Sarbecovirus, Respiratory diseases, Zoonoses, Animal diseases, Variants of SARS-CoV-2, Taconic Biosciences, Angiotensin-converting enzyme 2, Severe acute respiratory syndrome coronavirus, COVID-19, Severe acute respiratory syndrome

b"RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model.

Key Points: 
  • b"RENSSELAER, N.Y., April 29, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces the launch of a new COVID-19 mouse model.
  • This human ACE2 (hACE2) transgenic mouse expands Taconic\xe2\x80\x99s COVID-19 research toolkit.\nIn October 2020, Taconic launched its first hACE2 model .
  • The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus that causes COVID-19.
  • Conversely, the new AC22 mouse is lethality-resistant, enabling therapeutic, vaccine, and post-infection symptom research.\nAlthough various hACE2 mouse models of lethal SARS-CoV-2 infection exist, the hACE2 AC22 lethality-resistant model is important because it permits study of sublethal infection.

Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2021 Financial and Operational Results on May 10, 2021

Retrieved on: 
Tuesday, April 27, 2021
Animal diseases, Branches of biology, Organic compounds, HIV/AIDS, Tremellomycetes, Zoonoses, Medical emergencies, Fish products, Cryptococcosis, Meningitis, Ethyl eicosapentaenoic acid, Eicosapentaenoic acid

ET to discuss operational and financial results for the first quarter ended March 31, 2021.\nTo participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll).

Key Points: 
  • ET to discuss operational and financial results for the first quarter ended March 31, 2021.\nTo participate in the call, please dial (877) 407-5976 (Toll-Free) or (412) 902-0031 (Toll).
  • MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis.
  • Data demonstrating superior levels of eicosapentaenoic acid (EPA) in the blood with LYPDISO support the potential superior cardioprotective effect of LYPDISO vs. Vascepa.
  • Matinas BioPharma\xe2\x80\x99s product candidates are all in a development stage and are not available for sale or use.\n'

 Blueair’s HealthProtect™ Becomes First Air Purifier from Major Brand Tested to Remove Live SARS-CoV-2 Virus from Air

Retrieved on: 
Monday, April 12, 2021
Other Retail, Consumer electronics, Technology, Other Health, Health, General Health, Medical devices, Infectious diseases, Retail, Home Goods, Hardware, Sarbecovirus, Zoonoses, Animal diseases, Respiratory diseases, Purifier, Severe acute respiratory syndrome, Air purifier, Biosafety level, Blueair, MRIGlobal

b'Blueair , a global air purification expert, confirmed today its HealthProtect\xe2\x84\xa2 7400 air purifier removed 99.99%i of live airborne SARS-CoV-2 virus in controlled biosafety level 3 lab testing.

Key Points: 
  • b'Blueair , a global air purification expert, confirmed today its HealthProtect\xe2\x84\xa2 7400 air purifier removed 99.99%i of live airborne SARS-CoV-2 virus in controlled biosafety level 3 lab testing.
  • The test was conducted by MRIGlobal, an independent non-profit research organization, in a 13ft\xc2\xb3 chamber on live aerosolized SARS-CoV-2 virus.
  • With today\xe2\x80\x99s announcement, Blueair\xe2\x80\x99s HealthProtect air purifier has become the first product from a majorii air purifier brand tested to remove the live SARS-CoV-2 virus from the air.\nThis press release features multimedia.
  • \xe2\x80\x9cBlueair has built its position as a leader within the air purification industry by 25 years of independent third-party testing of all innovations.

airKAVE Portable Air Purifier Now Approved To Combat COVID-19

Retrieved on: 
Thursday, April 15, 2021
Sarbecovirus, Zoonoses, Animal diseases, Infectious diseases, Coronavir, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome

b'LOS ANGELES, April 15, 2021 /PRNewswire/ --airKAVE, the world\'s most advanced air purification technology, announced today that the airKAVE Portable passedthe Characterization of Model AH01 Air Purification Device in Deactivation of Aerosolized SARS-COV-2 test (from MRIGlobal).

Key Points: 
  • b'LOS ANGELES, April 15, 2021 /PRNewswire/ --airKAVE, the world\'s most advanced air purification technology, announced today that the airKAVE Portable passedthe Characterization of Model AH01 Air Purification Device in Deactivation of Aerosolized SARS-COV-2 test (from MRIGlobal).
  • The test confirms that airKAVE Portable destroys aerosolized SARS-CoV-2 within a fraction of a second as the air passes through the filterless device providing personal protection against the Coronavirus (COVID-19.
  • "\nThanks to its patented filterless Plascide plasma technology, airKAVE works like no other air purification system on the market destroying microorganisms at the molecular level.
  • With airKAVE, air is pulled into the internal Plascide reactor, creating a thunderstorm of micro-lightning plasma which puts the microscopic particles into an electrified state at room temperature.